CARES Act Impact on Health Care

Health Care   |   March 31, 2020
Download Download   
Share Share Page

Carlton Fields Coronavirus Resource Center

On March 27, 2020, President Trump signed the Coronavirus Aid, Relief, and Economic Security (CARES) Act. The CARES Act provides a relief package that pushes $2 trillion into the U.S. economy by providing financial assistance to millions of American individuals, businesses, and industries affected by the COVID-19 pandemic. The CARES Act contains several significant measures benefitting the health care industry, the frontline for battling this pandemic. These measures include:

Monetary Support

  • $100 billion in funds has been allocated to reimburse health care providers for expenses incurred in treating COVID-19 patients. Health care providers will need to submit the required documentation to the secretary of the Department of Health and Human Services in order to receive these funds.
  • $1.32 billion will be provided to federally qualified health centers for fiscal year 2020 through supplemental awards for the prevention, diagnosis, and treatment of COVID-19.


  • The secretary may accelerate Medicare payments to hospitals on a periodic or lump sum basis.
  • Repayment of the accelerated payments to hospitals will be delayed for 120 days and repayment can be done over a 12-month period.
  • There will be a 20% increase in the diagnosis-related group rate for COVID-19 patients.
  • Medicare sequestration will be temporarily suspended from May 1, 2020, through December 31, 2020.
  • Patients may receive prescription drugs for a 90-day period.
  • The 50% rule or site-neutral payment policies for long-term care hospitals will be waived, allowing for increased capacity.


  • Reduction in disproportionate share hospital payments are delayed until December 1, 2020.
  • Spousal impoverishment protections are extended through November 30, 2020.


  • The secretary shall encourage the use of telehealth services during the emergency period.
  • Telehealth services may be provided to new patients, eliminating the preexisting patient relationship requirement.
  • The requirement of face-to-face visits for home dialysis and hospice patients is waived for the emergency period.
  • Cost-sharing for telehealth services has been waived.
  • Rural health clinics and federally qualified health centers may serve as distant site providers for telehealth services.

Testing and Preventative Services

  • Diagnostic testing for the detection of COVID-19 is approved and authorized.
  • $11 billion is being provided for diagnostics, treatment, and vaccines for COVID-19.
  • Health insurance plans must cover COVID-19 diagnostic tests without cost-sharing.
  • Providers of a diagnostic test for COVID-19, who have not negotiated a rate with health insurance plans, must publish the cash price for each test on their public website for the duration of the emergency period. Failure to publish such pricing could result in penalties of up to $300 per day.

Medical Device and Drug Shortages

  • The secretary is instructed to prioritize the review of applications for drugs that are critical to the public health during this emergency.
  • Manufacturers of drugs critical to the public health must develop and implement a risk management plan identifying and evaluating the risks of supplying such drug.
  • $80 million is being provided to the Food and Drug Administration to prioritize and expedite the approval of COVID-19 drugs.
  • The manufacturer of a medical device critical during a public health emergency, or devices the secretary deems essential, must notify the secretary of a permanent discontinuance in the manufacture of the device (unless it is a result of an approved modification) or a significant interruption in manufacture of the device.

Health Care Supplies

  • The secretary is instructed to work with the National Academies of Sciences, Engineering, and Medicine to assess and evaluate the supply chain of critical drugs and devices for providing health care in order to make recommendations for improving the resiliency and address vulnerabilities or potential disruptions.
  • The Strategic National Stockpile is expanded to include certain personal protective equipment, ancillary medical supplies, and other essential supplies.
  • $16 billion is available to increase supplies and equipment in the Strategic National Stockpile.
  • Respiratory protective devices are added as covered countermeasures for liability protections for pandemic and epidemic products.

©2023 Carlton Fields, P.A. Carlton Fields practices law in California through Carlton Fields, LLP. Carlton Fields publications should not be construed as legal advice on any specific facts or circumstances. The contents are intended for general information and educational purposes only, and should not be relied on as if it were advice about a particular fact situation. The distribution of this publication is not intended to create, and receipt of it does not constitute, an attorney-client relationship with Carlton Fields. This publication may not be quoted or referred to in any other publication or proceeding without the prior written consent of the firm, to be given or withheld at our discretion. To request reprint permission for any of our publications, please use our Contact Us form via the link below. The views set forth herein are the personal views of the author and do not necessarily reflect those of the firm. This site may contain hypertext links to information created and maintained by other entities. Carlton Fields does not control or guarantee the accuracy or completeness of this outside information, nor is the inclusion of a link to be intended as an endorsement of those outside sites.

Subscribe to Publications


The information on this website is presented as a service for our clients and Internet users and is not intended to be legal advice, nor should you consider it as such. Although we welcome your inquiries, please keep in mind that merely contacting us will not establish an attorney-client relationship between us. Consequently, you should not convey any confidential information to us until a formal attorney-client relationship has been established. Please remember that electronic correspondence on the internet is not secure and that you should not include sensitive or confidential information in messages. With that in mind, we look forward to hearing from you.